genia tagger: 240('pcna', 18)
('oncogenes', 2)
('scc61', 22)
('phosphopkc', 2)
('cdk', 49)
('pkc', 520)
('ffl', 8)
('hela', 2)
('human', 21)
('expression\\.', 12)
('rellina', 4)
('marker', 8)
('-tubulin', 4)
('mir-16-1', 3)
('unique', 4)
('cancer', 14)
('anti-pkc', 8)
('\\?', 558)
('untranslated', 4)
('kinase', 30)
('reporter-expressing', 2)
('mcm6', 10)
('xenografts', 12)
('actin', 2)
('4', 163)
('cyclin-dependent', 2)
('factor', 11)
('mir-17-5p', 1)
('suppressor', 8)
('\\(', 533)
('\\)', 575)
('abundance', 4)
('pcr\\.', 2)
('microrna', 7)
('3', 193)
('dependent', 45)
('rna', 121)
('mir-15a', 134)
('inhibition', 105)
('e2f1-3', 1)
('e2f2\\.', 4)
('cyclin', 306)
('reporters', 4)
('1b', 8)
('g\xc3\xb66976-treated', 4)
('untreated', 22)
('e2f2', 56)
('anti-cdk2', 2)
('and', 435)
('d', 2952)
('pbs', 2)
('significance\\.', 2)
('mir-15-a', 39)
('p-pkc', 4)
('proteins', 18)
('specific', 17)
('2a', 4)
('mrna', 15)
('cells', 172)
('statistical', 6)
('scchn', 115)
('proliferating', 10)
('supplementary', 4)
('anti-', 46)
('growth', 47)
('5b', 4)
('ep', 149)
('cofactor', 4)
('mut', 26)
('oncogene', 3)
('d-rb-e2f', 2)
('network', 9)
('factors', 5)
('gsk3', 2)
('complementary', 6)
('sites', 12)
('cell', 328)
('enhancement\\.', 4)
('cyclin-activated', 3)
('-utr-containing', 4)
('rb', 15)
('serum-starved', 12)
('3b', 8)
('3a', 12)
('isoforms', 24)
('pkcs', 4)
('suppresses', 8)
('2b', 16)
('reporter', 12)
('mir-15', 177)
('genes', 40)
('-utr', 12)
('fig\\.', 156)
('holoenzyme', 4)
('luciferase', 18)
('members', 5)
('active', 1)
('e2fs', 6)
('analyses', 8)
('e1', 30)
('e2', 84)
('anti-phospho-pkc', 8)
('c', 4228)
('z', 76)
('serine\\/threonine', 5)
('biotin-labeled', 2)
('region', 12)
('vectors', 10)
('vectors\\.', 4)
('tumor', 117)
('turn', 6)
('wt', 61)
('e\\.', 46)
('raf\\-1\\/mapk', 2)
('gene', 89)
('antibody', 40)
('hct116', 2)
('anti-phospho', 12)
('family', 10)
('material', 4)
('egfr', 2)
('primary', 18)
('locus', 2)
('regulatory', 4)
('cdk2', 30)
('receptor', 2)
('e2f2-regulated', 4)
('oncogenic', 11)
('nih3t3', 2)
('cells\\.', 26)
('e1-dependent', 4)
('171', 4)
('ct', 443)
('1a', 12)
('phospho-antibody', 8)
('dna', 165)
('phospho-erk', 2)
('cancers\\.', 4)
('positive', 13)
('u6', 2)
('6b', 2)
('dfs', 16)
('cyclins', 13)
('mutated', 6)
('p2584', 2)
('2', 592)
('keratinocytes', 3)
('kinases', 4)
('-stimulated', 7)
('g\xc3\xb66976', 144)
('brdu', 36)
('g\\\xc3\\\xb66976\\.', 2)
('probes', 8)
('type', 13)
('low', 62)
('mcm', 20)
('maintenance', 4)
('raf-1', 4)
('6', 371)
('r2\\=0\\.22', 2)
('39', 10)
('coherent', 4)
('adult', 1)
('rabbit', 4)
('real-time', 4)
('line', 46)
('fl', 20)
('phospho-pkc', 16)
('epidermal', 1)
('target', 19)
('hn31', 10)
('mo', 239)
('minichromosome', 4)
('rnas', 6)
('sq20b', 124)
('promoter', 2)
('utr', 44)
('anti-cyclin', 4)
('wild', 2)
('synthesis\\.', 45)
('4\\/6', 3)
('treated', 70)
('loop', 16)
('erk', 21)
('raf', 24)
('motif', 4)
('figure', 14)
('binding', 12)
('site', 20)
('u2os', 2)
('rat', 153)
('ras', 44)
('protein', 136)
('mouse', 4)
('tov21g', 2)
('mrnas', 1)
('pre', 497)
('transcription', 14)
('ffls', 2)
('electroporation\\.', 2)
('1', 569)
('microarray', 20)
('e2f', 76)
('complex', 18)
('genome', 2)
('13q14', 2)
('mir16', 6)
('ubiquitin', 2)
('map', 38)
('fibroblasts', 2)
('multiple', 6)
('prognostic', 12)
('normal', 51)
('thr641', 4)
('leukemic', 2)
('polymerase', 4)
('3y1', 2)
('000', 16)
('rho', 4)
('21-23', 1)
('alpha', 16)
('nucleotide', 1)
('cycle', 49)
('a', 5841)
('antibodies', 6)
('e', 9950)
('enzymes', 4)
('expression', 254)
('rb\\.', 2)
('ligases', 2)
('lines', 32)
('anti-mir-15a', 6)
('lscc', 4)
('mapk', 34)
('cal27', 10)
('quantitative', 12)
('bcl-2', 2)
('4b', 16)
('egf', 11)
('4a', 8)


spacy + metamap: 657('limited', 8)
('positive control', 2)
('activated', 11)
('inducer', 4)
('papilloma', 1)
('rapid', 14)
('data sets', 4)
('dysplasia', 1)
('edu', 72)
('integrity', 2)
('cyclin e1', 20)
('number', 4)
('pretreatment', 4)
('containing', 14)
('foster', 2)
('heterogeneity', 4)
('case', 8)
('assay', 14)
('apoptosis', 2)
('activation', 61)
('induce', 29)
('rna purification', 2)
('replication', 8)
('difference', 12)
('micrornas', 2)
('condition', 6)
('malignant disease', 1)
('four', 4)
('progression', 27)
('level', 69)
('stimulus', 7)
('leukemic cell', 2)
('immune cell function', 2)
('egf receptor', 2)
('phosphorylation', 9)
('pkcalpha', 2)
('washout', 4)
('cell lines', 32)
('upper', 2)
('oncogen', 14)
('serum-free media', 8)
('dna synthesis', 139)
('genechip', 2)
('scchn', 115)
('triplicate', 2)
('trend', 4)
('consistent', 31)
('fold', 14)
('rate', 46)
('enhancement', 8)
('further', 33)
('mtt', 8)
('abi', 19)
('section', 8)
('selected', 8)
('cyclin-dependent kinases', 2)
('experiment', 53)
('3c', 4)
('3b', 8)
('net', 35)
('increasing', 2)
('isoforms', 24)
('contrast', 18)
('electroporation', 2)
('proliferation', 20)
('reporter', 12)
('genes', 40)
('mek', 2)
('hours', 60)
('reported', 4)
('inverse', 13)
('others', 4)
('active', 1)
('change', 38)
('institutional review board', 2)
('precursor', 8)
('shift', 4)
('31', 14)
('vectors', 10)
('graph', 4)
('cessation', 2)
('biopsies', 4)
('gene', 89)
('changes', 22)
('family', 10)
('mediator', 15)
('highly', 12)
('decrease', 48)
('licensing', 2)
('translational', 1)
('marker', 8)
('tumor sample', 12)
('total', 14)
('dna', 165)
('cell proliferation', 10)
('positive', 13)
('control vector', 4)
('negative', 19)
('xenografts', 12)
('mirna', 20)
('ip', 57)
('brdu', 36)
('panel', 46)
('regulatory genes', 4)
('cyclin d', 6)
('cyclin e', 276)
('0\\%', 8)
('proliferative', 8)
('qrt-pcr', 10)
('tail vein', 2)
('envelope', 1)
('mcm protein', 4)
('right hind limb', 2)
('transient', 5)
('normalized', 14)
('supplemental', 32)
('abundance', 4)
('high', 32)
('ma', 273)
('hour', 64)
('map kinase', 2)
('mo', 239)
('work', 11)
('labeled', 2)
('values', 8)
('protein synthesis', 25)
('inhibitor', 45)
('example', 2)
('10\\%', 6)
('erk', 21)
('control', 50)
('mapk signaling', 8)
('mirrors', 4)
('process', 3)
('immune system', 2)
('sample', 42)
('death', 8)
('serum', 80)
('recovery', 4)
('turn', 6)
('discussion', 2)
('feature', 2)
('delay', 4)
('prognosis', 6)
('significance', 12)
('upregulation', 2)
('pathway', 4)
('map', 38)
('prognostic', 12)
('tailed', 2)
('derived', 3)
('replication fork', 4)
('polymerase', 4)
('data', 51)
('response', 20)
('clinical trials', 2)
('neck', 6)
('overexpression', 16)
('enzymes', 4)
('cell cycle deregulation', 1)
('cascade', 11)
('30 minutes', 2)
('correlation', 6)
('1a', 12)
('pcna', 18)
('feedback', 6)
('primary tumors', 2)
('experiments', 24)
('hela', 2)
('left', 24)
('staining', 34)
('epidermal growth factor', 1)
('cyclin e overexpression', 8)
('group', 6)
('23', 5)
('pcr', 28)
('decreases', 13)
('late', 131)
('mcm6', 10)
('absence', 2)
('fig', 170)
('decreased', 14)
('mrna translation', 4)
('immunoblot', 20)
('maximal', 10)
('combination', 2)
('gray', 2)
('vitro', 20)
('effects', 30)
('not', 76)
('locus', 2)
('association', 3)
('pbs', 2)
('university', 2)
('proteins', 18)
('endocrine pancreatic tumors', 2)
('2d', 4)
('2b', 16)
('cyclin e gene amplification', 2)
('higher', 5)
('typical', 3)
('mean', 10)
('week', 4)
('cancer cells', 2)
('cell cycle arrest', 2)
('independent', 24)
('proliferating', 10)
('mm3', 2)
('binding sites', 6)
('laboratory', 2)
('negative regulation', 6)
('network', 9)
('tissue array analysis', 1)
('increase', 37)
('kinase activity', 8)
('mediated', 7)
('dysplastic', 24)
('induced', 11)
('induction', 14)
('dmso', 2)
('immunohistochemistry', 8)
('mechanisms', 10)
('free', 20)
('tumor recurrence', 2)
('regulators', 3)
('likelihood', 2)
('dose response', 4)
('e2', 84)
('hind limb', 6)
('r2', 2)
('times', 2)
('proteosome', 8)
('tumor growth', 13)
('proportional hazards model', 8)
('first', 2)
('feed', 20)
('total protein', 6)
('initial', 7)
('student', 2)
('probability', 10)
('radioresistant', 4)
('primary', 18)
('rank', 10)
('one', 26)
('specificity', 4)
('array', 29)
('size', 4)
('squamous cell carcinoma', 4)
('city', 6)
('findings', 6)
('fifty', 4)
('fl', 20)
('top', 8)
('system', 8)
('approximately', 2)
('stimulation', 8)
('regulation', 48)
('keratinocytes', 3)
('white', 2)
('recent', 8)
('schema', 2)
('relationship', 10)
('continuous', 4)
('antibodies', 6)
('part', 13)
('signaling', 17)
('translation', 15)
('expression vectors', 2)
('detection', 2)
('e2f2', 56)
('isolation', 8)
('cyclin', 306)
('database', 4)
('second', 2)
('significantly high', 4)
('regulator', 8)
('patients', 5)
('individual', 6)
('lysate', 10)
('outcome', 11)
('treated', 70)
('result', 104)
('raf', 24)
('sam', 50)
('spectrum', 1)
('20a', 1)
('raw', 2)
('cell cycle transition', 4)
('medium', 6)
('untranslated region', 4)
('cell types', 2)
('transcription', 14)
('mechanism', 32)
('majority', 2)
('potential', 4)
('13q14', 2)
('mir16', 6)
('competence', 4)
('multiple', 6)
('proteosome inhibitor', 4)
('supplementary material', 4)
('normal', 51)
('tumor microenvironment', 2)
('cell cycle', 49)
('significant', 39)
('phase', 13)
('nucleotide', 1)
('probes', 8)
('initiator', 1)
('observation', 4)
('neighboring', 4)
('average', 2)
('protein expression', 26)
('flow', 2)
('graphs', 2)
('cell survival', 2)
('pattern', 4)
('family members', 5)
('mtt assay', 6)
('oncogenes', 2)
('probe', 20)
('cdk', 49)
('pkc', 520)
('malignant', 25)
('threshold', 4)
('aggressive', 8)
('availability', 4)
('cell', 328)
('slow', 8)
('ratio', 73)
('s phase', 11)
('expression measurement', 4)
('proportion', 12)
('kinase', 30)
('terminal', 3)
('actin', 2)
('factor', 11)
('extracellular', 2)
('dependent', 45)
('overall', 4)
('degradation', 14)
('breast', 1)
('reporters', 4)
('conjunction', 4)
('untreated', 22)
('target', 19)
('stability', 1)
('bar', 8)
('progressive', 5)
('tumors', 28)
('differential', 8)
('median', 4)
('alteration', 1)
('predicted', 4)
('activity', 30)
('black', 4)
('keratinocyte differentiation', 3)
('bars', 8)
('set', 10)
('sensitivity', 4)
('approved protocol', 2)
('relative', 19)
('culture', 4)
('intensity', 14)
('cytoplasmic', 4)
('dna helicases', 4)
('enhanced', 6)
('mediators', 1)
('arm', 10)
('cofactor', 4)
('mut', 26)
('oncogene', 3)
('inhibitory', 2)
('xenograft model', 1)
('subsequent', 4)
('sites', 12)
('inhibitors', 9)
('tumor suppressor', 6)
('numerous', 2)
('pkcs', 4)
('rb protein', 4)
('recently', 6)
('screen', 2)
('suppresses', 8)
('efficiency', 1)
('wt', 61)
('extent', 4)
('terminal differentiation', 2)
('competent', 4)
('reaction', 4)
('survival', 16)
('3\\+', 12)
('deregulation', 3)
('region', 12)
('apoptotic process', 1)
('drug', 16)
('context', 1)
('contribution', 2)
('expression', 254)
('pre', 497)
('luciferase activity', 8)
('cancer', 14)
('point', 2)
('mutations', 2)
('\\/week', 4)
('regulated', 10)
('raf-1', 4)
('respect', 8)
('ct', 443)
('described', 44)
('addition', 31)
('three', 12)
('cyclins', 13)
('extraction', 2)
('cellular physiology', 1)
('initiation', 4)
('treatment', 58)
('mcm', 20)
('controlled', 1)
('efficacy', 2)
('24 hours', 32)
('coherent', 4)
('representative', 10)
('cyclin e gene', 4)
('evidence', 12)
('former', 4)
('present', 35)
('additional procedure', 2)
('novel', 4)
('quantification', 4)
('tubulin', 4)
('suppressor', 8)
('mapk cascade', 2)
('rat', 153)
('promoter', 2)
('2\\+', 8)
('transcripts', 2)
('sirna', 64)
('study', 5)
('loop', 16)
('ras', 44)
('disease-free survival', 10)
('poor prognosis', 4)
('motif', 4)
('almost', 4)
('characteristics', 4)
('cell growth', 21)
('site', 20)
('middle', 2)
('tissue', 62)
('brake', 5)
('tumor cell', 31)
('dual', 8)
('aggressiveness', 4)
('protein', 136)
('ib', 307)
('mouse', 4)
('increased', 23)
('mapk activation', 10)
('cohort', 5)
('confirmed', 20)
('baseline', 4)
('cumulative', 2)
('administration', 4)
('same', 6)
('microarray', 20)
('stimulated', 7)
('complex', 18)
('phenotype', 2)
('events', 5)
('minichromosome maintenance proteins', 4)
('development', 3)
('transcription factor', 2)
('http', 4)
('disease recurrence', 8)
('driver', 4)
('effect', 51)
('kit', 2)
('levels', 63)
('cell signaling', 3)
('gsk3', 2)
('cycle', 49)
('lower', 15)
('possibly', 8)
('studies', 7)
('stimuli', 5)
('analysis', 39)
('components', 3)
('model', 13)
('oral epithelium', 4)
('ic50', 4)
('less', 10)
('stroma', 6)
('ubiquitin', 2)
('human', 21)
('previous', 25)
('visualization', 4)
('luciferase', 18)
('catalytic', 4)
('advancement', 2)
('10 hours', 4)
('relevance', 3)
('input', 4)
('transformation', 2)
('bio', 12)
('microrna', 7)
('rna', 121)
('cell lysate', 4)
('early', 2)
('protein kinase c alpha', 2)
('inhibition', 105)
('five', 4)
('unique', 4)
('prominent', 4)
('loss', 22)
('outcome measure', 8)
('55', 2)
('signal', 22)
('specific', 17)
('either', 20)
('reduced', 21)
('therapeutic', 2)
('cellular process', 1)
('right', 22)
('arrested', 4)
('dose-dependent', 4)
('growth', 47)
('intact', 4)
('cell cycle regulation', 4)
('fibroblasts', 2)
('protein level', 34)
('scale', 4)
('bottom', 4)
('broad', 3)
('whole', 2)
('repression', 4)
('depletion', 25)
('critical', 9)
('mutation', 6)
('tissue sample', 2)
('gene expression', 23)
('participation', 1)
('patient', 13)
('mrna', 15)
('experimental procedures', 27)
('cell cycle proteins', 2)
('cornification', 1)
('cell cycle regulator', 1)
('mitogen', 2)
('mir15a', 1)
('stage', 4)
('comparison', 4)
('tissue section', 4)
('e2f2 protein', 16)
('months', 8)
('tumor', 117)
('important', 4)
('mg132', 6)
('concentrations', 2)
('antibody', 40)
('predictor', 8)
('block', 8)
('pathways', 2)
('rationale', 2)
('presence', 6)
('integral', 1)
('functional', 2)
('two', 23)
('cdk2', 30)
('lung', 1)
('female', 8)
('proteolysis', 4)
('prognostic marker', 4)
('additional', 13)
('transcript', 22)
('u6', 2)
('reduction', 4)
('long', 4)
('clinical', 4)
('hepatocellular carcinoma', 1)
('low', 62)
('hnscc', 1)
('series', 2)
('forward', 16)
('specimens', 4)
('metabolism', 4)
('synthesis', 175)
('function', 19)
('starve', 16)
('head', 6)
('cell line', 40)
('complete', 8)
('70\\%', 2)
('expression level', 4)
('keratinocyte', 6)
('introduction', 1)
('heat', 2)
('incorporation', 36)
('elimination', 4)
('immunoblotting', 16)
('line', 46)
('type', 13)
('cells', 172)
('rnas', 6)
('vivo', 12)
('different', 26)
('utr', 44)
('paired', 2)
('cancers', 8)
('mature', 2)
('distribution', 4)
('similar', 26)
('ligases', 2)
('classic', 6)
('regression analysis', 2)
('curve', 6)
('48 hours', 6)
('tissues', 11)
('general', 7)
('immunoprecipitation', 6)
('diverse', 3)
('helicase', 6)
('follow-up', 4)
('statistical significance', 6)
('functions', 2)
('cyclin e1 gene', 4)
('nm', 76)
('variety', 3)
('cell cycle genes', 8)
('inactivation', 10)
('role', 11)
('test', 24)
('transfection', 16)
('elements', 2)
('immunoprecipitate', 4)
('separate', 2)
('15a', 137)
('signaling cascade', 9)
('log', 17)
('suppression', 7)
('variable', 4)
('laryngeal squamous cell carcinomas', 2)
('fold change', 10)
('exposure', 4)
('lane', 2)
('bcl-2', 2)
('human tissue', 2)
('30 minute', 2)
('kinetics', 24)
('cell cycle progression', 11)
('time course', 8)
('time', 18)
('12 hours', 16)
('biotechnology', 2)
('angiogenesis', 4)
('oral mucosa', 9)
('biotin', 2)


total: 786('limited', 8)
('positive control', 2)
('proteolysis', 4)
('activated', 11)
('inducer', 4)
('papilloma', 1)
('rapid', 14)
('data sets', 4)
('dysplasia', 1)
('edu', 72)
('integrity', 2)
('g\\\xc3\\\xb66976\\.', 2)
('number', 4)
('system', 8)
('pretreatment', 4)
('containing', 14)
('phospho-erk', 2)
('xenografts', 12)
('heterogeneity', 4)
('4\\/6', 3)
('case', 8)
('assay', 14)
('dysplastic', 24)
('apoptosis', 2)
('activation', 61)
('anti-mir-15a', 6)
('induce', 29)
('rna purification', 2)
('replication', 8)
('difference', 12)
('micrornas', 2)
('condition', 6)
('malignant disease', 1)
('four', 4)
('pre', 497)
('pbs', 2)
('level', 69)
('stimulus', 7)
('gene expression', 23)
('immune cell function', 2)
('egf receptor', 2)
('phosphorylation', 9)
('pkcalpha', 2)
('washout', 4)
('cell lines', 32)
('upper', 2)
('oncogen', 14)
('serum-free media', 8)
('dna synthesis', 139)
('genechip', 2)
('scchn', 115)
('triplicate', 2)
('trend', 4)
('consistent', 31)
('fold', 14)
('rate', 46)
('enhancement', 8)
('further', 33)
('mtt', 8)
('abi', 19)
('section', 8)
('selected', 8)
('cyclin-dependent kinases', 2)
('experiment', 53)
('3c', 4)
('3b', 8)
('3a', 12)
('increasing', 2)
('isoforms', 24)
('contrast', 18)
('electroporation', 2)
('proliferation', 20)
('anti-cyclin', 4)
('reporter', 12)
('genes', 40)
('mek', 2)
('-utr', 12)
('reported', 4)
('cyclin e1', 20)
('others', 4)
('active', 1)
('change', 38)
('institutional review board', 2)
('39', 10)
('precursor', 8)
('shift', 4)
('study', 5)
('vectors', 10)
('phospho-pkc', 16)
('graph', 4)
('cessation', 2)
('biopsies', 4)
('gene', 89)
('studies', 7)
('family', 10)
('mediator', 15)
('egfr', 2)
('increased', 23)
('highly', 12)
('decrease', 48)
('licensing', 2)
('translational', 1)
('marker', 8)
('tumor sample', 12)
('total', 14)
('10 hours', 4)
('dna', 165)
('cell proliferation', 10)
('positive', 13)
('control vector', 4)
('negative', 19)
('foster', 2)
('mirna', 20)
('g\xc3\xb66976', 144)
('brdu', 36)
('panel', 46)
('type', 13)
('cyclin d', 6)
('cyclin e', 276)
('0\\%', 8)
('proliferative', 8)
('qrt-pcr', 10)
('tail vein', 2)
('r2\\=0\\.22', 2)
('mcm protein', 4)
('right hind limb', 2)
('transient', 5)
('adult', 1)
('rabbit', 4)
('real-time', 4)
('supplemental', 32)
('abundance', 4)
('high', 32)
('ma', 273)
('r2', 2)
('hour', 64)
('map kinase', 2)
('mo', 239)
('work', 11)
('labeled', 2)
('values', 8)
('protein synthesis', 25)
('inhibitor', 45)
('example', 2)
('10\\%', 6)
('erk', 21)
('control', 50)
('mapk signaling', 8)
('figure', 14)
('mirrors', 4)
('process', 3)
('immune system', 2)
('u2os', 2)
('sample', 42)
('death', 8)
('serum', 80)
('recovery', 4)
('proteosome', 8)
('mapk', 34)
('discussion', 2)
('feature', 2)
('1', 569)
('prognosis', 6)
('e2f', 76)
('significance', 12)
('upregulation', 2)
('pathway', 4)
('map', 38)
('prognostic', 12)
('less', 10)
('tailed', 2)
('derived', 3)
('replication fork', 4)
('leukemic', 2)
('polymerase', 4)
('3y1', 2)
('data', 51)
('response', 20)
('synthesis\\.', 45)
('a', 5841)
('neck', 6)
('overexpression', 16)
('enzymes', 4)
('lines', 32)
('cell cycle deregulation', 1)
('cascade', 11)
('30 minutes', 2)
('thr641', 4)
('egf', 11)
('family members', 5)
('pcna', 18)
('feedback', 6)
('biotin', 2)
('phosphopkc', 2)
('g\xc3\xb66976-treated', 4)
('primary tumors', 2)
('ffl', 8)
('hela', 2)
('statistical', 6)
('left', 24)
('staining', 34)
('rellina', 4)
('-tubulin', 4)
('delay', 4)
('mir-16-1', 3)
('group', 6)
('23', 5)
('pcr', 28)
('presence', 6)
('decreases', 13)
('late', 131)
('mcm6', 10)
('absence', 2)
('fig', 170)
('cyclin-dependent', 2)
('mir-17-5p', 1)
('decreased', 14)
('mrna translation', 4)
('suppressor', 8)
('maximal', 10)
('combination', 2)
('ffls', 2)
('material', 4)
('vitro', 20)
('e2f2\\.', 4)
('not', 76)
('association', 3)
('progression', 27)
('significance\\.', 2)
('mir-15-a', 39)
('university', 2)
('proteins', 18)
('endocrine pancreatic tumors', 2)
('2d', 4)
('2a', 4)
('mrna', 15)
('cyclin e gene amplification', 2)
('receptor', 2)
('minichromosome maintenance proteins', 4)
('typical', 3)
('mean', 10)
('week', 4)
('cancer cells', 2)
('cell cycle arrest', 2)
('independent', 24)
('proliferating', 10)
('cyclin e overexpression', 8)
('oncogenic', 11)
('binding sites', 6)
('laboratory', 2)
('ep', 149)
('negative regulation', 6)
('network', 9)
('factors', 5)
('tissue array analysis', 1)
('increase', 37)
('kinase activity', 8)
('mediated', 7)
('171', 4)
('rb', 15)
('induced', 11)
('induction', 14)
('dmso', 2)
('immunohistochemistry', 8)
('leukemic cell', 2)
('normalized', 14)
('mechanisms', 10)
('free', 20)
('tumor recurrence', 2)
('regulators', 3)
('members', 5)
('regulatory', 4)
('e1', 30)
('dose response', 4)
('epidermal growth factor', 1)
('e2', 84)
('hind limb', 6)
('mitogen', 2)
('serine\\/threonine', 5)
('biotin-labeled', 2)
('times', 2)
('turn', 6)
('levels', 63)
('e\\.', 46)
('tumor growth', 13)
('proportional hazards model', 8)
('first', 2)
('feed', 20)
('total protein', 6)
('u6', 2)
('student', 2)
('probability', 10)
('radioresistant', 4)
('primary', 18)
('rank', 10)
('one', 26)
('approximately', 2)
('specificity', 4)
('anti-', 46)
('array', 29)
('e1-dependent', 4)
('-utr-containing', 4)
('size', 4)
('squamous cell carcinoma', 4)
('city', 6)
('threshold', 4)
('e2fs', 6)
('findings', 6)
('introduction', 1)
('fl', 20)
('top', 8)
('regulation', 48)
('dfs', 16)
('1a', 12)
('p2584', 2)
('1b', 8)
('keratinocytes', 3)
('white', 2)
('oral epithelium', 4)
('schema', 2)
('-stimulated', 7)
('relationship', 10)
('clinical trials', 2)
('continuous', 4)
('lower', 15)
('part', 13)
('signaling', 17)
('translation', 15)
('expression vectors', 2)
('epidermal', 1)
('detection', 2)
('e2f2', 56)
('isolation', 8)
('cyclin', 306)
('database', 4)
('second', 2)
('significantly high', 4)
('regulator', 8)
('patients', 5)
('individual', 6)
('lysate', 10)
('synthesis', 175)
('treated', 70)
('dna helicases', 4)
('and', 435)
('sam', 50)
('spectrum', 1)
('20a', 1)
('raw', 2)
('rat', 153)
('medium', 6)
('ras', 44)
('p-pkc', 4)
('tov21g', 2)
('cell types', 2)
('transcription', 14)
('mechanism', 32)
('anti-pkc', 8)
('potential', 4)
('13q14', 2)
('mir16', 6)
('competence', 4)
('multiple', 6)
('proteosome inhibitor', 4)
('supplementary material', 4)
('normal', 51)
('correlation', 6)
('tumor microenvironment', 2)
('cell cycle', 49)
('rho', 4)
('net', 35)
('phase', 13)
('alpha', 16)
('nucleotide', 1)
('probes', 8)
('initiator', 1)
('observation', 4)
('neighboring', 4)
('average', 2)
('protein expression', 26)
('flow', 2)
('graphs', 2)
('cell survival', 2)
('lscc', 4)
('subsequent', 4)
('cal27', 10)
('bcl-2', 2)
('mtt assay', 6)
('oncogenes', 2)
('probe', 20)
('cdk', 49)
('pkc', 520)
('malignant', 25)
('expression\\.', 12)
('aggressive', 8)
('availability', 4)
('cell', 328)
('slow', 8)
('ratio', 73)
('s phase', 11)
('tumor suppressor', 6)
('expression measurement', 4)
('untranslated', 4)
('proportion', 12)
('kinase', 30)
('reporter-expressing', 2)
('terminal', 3)
('actin', 2)
('factor', 11)
('extracellular', 2)
('ip', 57)
('anti-cdk2', 2)
('dependent', 45)
('overall', 4)
('degradation', 14)
('e2f1-3', 1)
('breast', 1)
('reporters', 4)
('2', 592)
('conjunction', 4)
('untreated', 22)
('target', 19)
('stability', 1)
('bar', 8)
('progressive', 5)
('tumors', 28)
('differential', 8)
('median', 4)
('alteration', 1)
('experiments', 24)
('predicted', 4)
('activity', 30)
('rationale', 2)
('black', 4)
('keratinocyte differentiation', 3)
('bars', 8)
('set', 10)
('sensitivity', 4)
('approved protocol', 2)
('relative', 19)
('culture', 4)
('intensity', 14)
('cytoplasmic', 4)
('result', 104)
('enhanced', 6)
('mediators', 1)
('arm', 10)
('cofactor', 4)
('mut', 26)
('oncogene', 3)
('d-rb-e2f', 2)
('likelihood', 2)
('inhibitory', 2)
('xenograft model', 1)
('gsk3', 2)
('sites', 12)
('inhibitors', 9)
('enhancement\\.', 4)
('3', 193)
('numerous', 2)
('pkcs', 4)
('rb protein', 4)
('recently', 6)
('complementary', 6)
('screen', 2)
('suppresses', 8)
('efficiency', 1)
('holoenzyme', 4)
('wt', 61)
('extent', 4)
('terminal differentiation', 2)
('competent', 4)
('reaction', 4)
('c', 4228)
('outcome', 11)
('survival', 16)
('fig\\.', 156)
('deregulation', 3)
('region', 12)
('hours', 60)
('apoptotic process', 1)
('drug', 16)
('context', 1)
('contribution', 2)
('expression', 254)
('raf', 24)
('anti-phospho', 12)
('luciferase activity', 8)
('cancer', 14)
('point', 2)
('mutations', 2)
('\\/week', 4)
('regulated', 10)
('raf-1', 4)
('respect', 8)
('ct', 443)
('phospho-antibody', 8)
('described', 44)
('addition', 31)
('three', 12)
('cyclins', 13)
('extraction', 2)
('cellular physiology', 1)
('initiation', 4)
('kinases', 4)
('maintenance', 4)
('treatment', 58)
('6b', 2)
('controlled', 1)
('efficacy', 2)
('gray', 2)
('24 hours', 32)
('coherent', 4)
('representative', 10)
('cyclin e gene', 4)
('evidence', 12)
('former', 4)
('present', 35)
('additional procedure', 2)
('novel', 4)
('hn31', 10)
('quantification', 4)
('tubulin', 4)
('immunoblot', 20)
('mapk cascade', 2)
('cell cycle transition', 4)
('promoter', 2)
('2\\+', 8)
('wild', 2)
('transcripts', 2)
('5b', 4)
('sirna', 64)
('31', 14)
('loop', 16)
('disease-free survival', 10)
('poor prognosis', 4)
('motif', 4)
('almost', 4)
('characteristics', 4)
('cell growth', 21)
('binding', 12)
('site', 20)
('middle', 2)
('pathways', 2)
('tissue', 62)
('brake', 5)
('tumor cell', 31)
('dual', 8)
('aggressiveness', 4)
('protein', 136)
('ib', 307)
('mouse', 4)
('ubiquitin', 2)
('mapk activation', 10)
('cohort', 5)
('confirmed', 20)
('baseline', 4)
('cumulative', 2)
('administration', 4)
('same', 6)
('microarray', 20)
('stimulated', 7)
('complex', 18)
('phenotype', 2)
('events', 5)
('higher', 5)
('development', 3)
('transcription factor', 2)
('cell lysate', 4)
('http', 4)
('disease recurrence', 8)
('driver', 4)
('effect', 51)
('kit', 2)
('000', 16)
('two', 23)
('cell signaling', 3)
('e2f2-regulated', 4)
('cycle', 49)
('antibodies', 6)
('possibly', 8)
('changes', 22)
('stimuli', 5)
('analysis', 39)
('components', 3)
('quantitative', 12)
('model', 13)
('effects', 30)
('ic50', 4)
('scc61', 22)
('stroma', 6)
('human', 21)
('previous', 25)
('visualization', 4)
('luciferase', 18)
('catalytic', 4)
('majority', 2)
('\\?', 558)
('advancement', 2)
('4', 163)
('relevance', 3)
('input', 4)
('transformation', 2)
('\\(', 533)
('\\)', 575)
('bio', 12)
('microrna', 7)
('rna', 121)
('mir-15a', 134)
('early', 2)
('protein kinase c alpha', 2)
('inhibition', 105)
('five', 4)
('untranslated region', 4)
('unique', 4)
('prominent', 4)
('loss', 22)
('outcome measure', 8)
('d', 2952)
('55', 2)
('signal', 22)
('specific', 17)
('either', 20)
('reduced', 21)
('therapeutic', 2)
('cellular process', 1)
('right', 22)
('arrested', 4)
('dose-dependent', 4)
('supplementary', 4)
('growth', 47)
('fifty', 4)
('intact', 4)
('electroporation\\.', 2)
('cell cycle regulation', 4)
('fibroblasts', 2)
('protein level', 34)
('scale', 4)
('bottom', 4)
('broad', 3)
('whole', 2)
('repression', 4)
('depletion', 25)
('critical', 9)
('mutation', 6)
('serum-starved', 12)
('tissue sample', 2)
('pattern', 4)
('pcr\\.', 2)
('immunoblotting', 16)
('participation', 1)
('3\\+', 12)
('patient', 13)
('2b', 16)
('experimental procedures', 27)
('mir-15', 177)
('cell cycle proteins', 2)
('cornification', 1)
('cell cycle regulator', 1)
('analyses', 8)
('mir15a', 1)
('stage', 4)
('comparison', 4)
('tissue section', 4)
('e2f2 protein', 16)
('months', 8)
('vectors\\.', 4)
('tumor', 117)
('important', 4)
('mg132', 6)
('concentrations', 2)
('antibody', 40)
('predictor', 8)
('block', 8)
('stimulation', 8)
('significant', 39)
('cyclin-activated', 3)
('integral', 1)
('functional', 2)
('locus', 2)
('21-23', 1)
('cdk2', 30)
('lung', 1)
('female', 8)
('nih3t3', 2)
('cells\\.', 26)
('prognostic marker', 4)
('additional', 13)
('cancers\\.', 4)
('transcript', 22)
('initial', 7)
('reduction', 4)
('long', 4)
('mutated', 6)
('clinical', 4)
('hepatocellular carcinoma', 1)
('low', 62)
('hnscc', 1)
('series', 2)
('forward', 16)
('specimens', 4)
('metabolism', 4)
('anti-phospho-pkc', 8)
('function', 19)
('starve', 16)
('head', 6)
('cell line', 40)
('complete', 8)
('70\\%', 2)
('6', 371)
('expression level', 4)
('keratinocyte', 6)
('heat', 2)
('incorporation', 36)
('mm3', 2)
('elimination', 4)
('human tissue', 2)
('line', 46)
('inverse', 13)
('regulatory genes', 4)
('cells', 172)
('minichromosome', 4)
('rnas', 6)
('sq20b', 124)
('vivo', 12)
('different', 26)
('utr', 44)
('paired', 2)
('cancers', 8)
('mature', 2)
('distribution', 4)
('z', 76)
('similar', 26)
('ligases', 2)
('classic', 6)
('regression analysis', 2)
('curve', 6)
('48 hours', 6)
('tissues', 11)
('mcm', 20)
('general', 7)
('immunoprecipitation', 6)
('diverse', 3)
('helicase', 6)
('raf\\-1\\/mapk', 2)
('follow-up', 4)
('statistical significance', 6)
('mrnas', 1)
('functions', 2)
('cyclin e1 gene', 4)
('nm', 76)
('variety', 3)
('cell cycle genes', 8)
('inactivation', 10)
('hct116', 2)
('role', 11)
('genome', 2)
('test', 24)
('transfection', 16)
('elements', 2)
('immunoprecipitate', 4)
('separate', 2)
('envelope', 1)
('15a', 137)
('signaling cascade', 9)
('recent', 8)
('log', 17)
('suppression', 7)
('variable', 4)
('laryngeal squamous cell carcinomas', 2)
('fold change', 10)
('exposure', 4)
('lane', 2)
('e', 9950)
('30 minute', 2)
('rb\\.', 2)
('kinetics', 24)
('cell cycle progression', 11)
('time course', 8)
('time', 18)
('12 hours', 16)
('biotechnology', 2)
('angiogenesis', 4)
('oral mucosa', 9)
('4b', 16)
('4a', 8)
